Erratum: Primary biliary cirrhosis and primary sclerosing cholangitis: A review featuring a women’s health perspective (Journal of Clinical and Translational Hepatology, (2014), 10.14218/JCTH.2014.00024);Primary biliary cirrhosis and primary sclerosing cholangitis: A review featuring a women’s health perspective

Journal of Clinical and Translational Hepatology

Volumn 2, Issue 4, 2014, Pages 266-284

  Marchioni Beery, Renée M ^a   Vaziri, Haleh ^a   Forouhar, Faripour ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Cholestasis; Fat soluble vitamin deficiency; Fatigue; Hyperlipidemia; Metabolic bone disease; Pregnancy; Primary biliary cirrhosis; Primary sclerosing cholangitis; Pruritus; Women s health

Indexed keywords

EID: 84989955738     PISSN: 22250719     EISSN: 23108819     Source Type: Journal    
DOI: 10.14218/JCTH.2015.00101     Document Type: Erratum

References (197)

1. Karlsen TH, Vesterhus M, Boberg KM. Controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis. Aliment Pharmacol Ther 2014;39:282–301. doi: 10.1111/apt.12581.
2. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012;56:1181–1188. doi: 10.1016/j.jhep.2011.10.025.
3. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ, et al. Primary biliary cirrhosis. Hepatology 2009;50:291–308. doi: 10.1002/hep.22906.
4. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005;353: 1261–1273. doi: 10.1056/NEJMra043898.
5. Bowlus CL, Gershwin ME. The diagnosis of primary biliary cirrhosis. Autoimmun Rev 2014;13:441–444. doi: 10.1016/j.autrev.2014.01.041.
6. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005;42:1194–1202. doi: 10.1002/hep.20907.
7. Parikh-Patel A, Gold EB, Worman H, Krivy KE, Gershwin ME. Risk factors for primary biliary cirrhosis in a cohort of patients from the United States. Hepatology 2001;33:16–21. doi: 10.1053/jhep.2001.21165.
8. Momah N, Lindor KD. Primary biliary cirrhosis in adults. Expert Rev Gastroenterol Hepatol 2014;8:427–433. doi: 10.1586/17474124.2014. 888950.
9. Parikh-Patel A, Gold E, Utts J, Gershwin ME. The association between gravidity and primary biliary cirrhosis. Ann Epidemiol 2002;12:264–272. doi: 10.1016/S1047-2797(01)00277-0.
10. Boonstra K, Kunst AE, Stadhouders PH, Tuynman HA, Poen AC, van Nieuwkerk KM, et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. Liver Int 2014;34:e31–e38. doi: 10.1111/liv.12434.
11. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51: 237–267. doi: 10.1016/j.jhep.2009.04.009.
12. Gotthardt D, Runz H, Keitel V, Fischer C, Flechtenmacher C, Wirtenberger M, et al. A mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults. Hepatology 2008;48:1157–1166. doi: 10.1002/hep.22485.
13. Kuiper EM, Zondervan PE, van Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol 2010;8:530–534. doi: 10.1016/j.cgh.2010.03.004.
14. Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002;123:1044–1051. doi: 10.1053/gast.2002.36027.
15. Springer J, Cauch-Dudek K, O’Rourke K, Wanless IR, Heathcote EJ. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol 1999;94:47–53.
16. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ, et al. Primary biliary cirrhosis. Hepatology 2009;50:291–308. doi: 10.1002/hep.22906.
17. Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000;32:1196–1199. doi: 10.1053/jhep.2000.20240.
18. Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2012;12: CD000551. doi: 10.1002/14651858.CD000551.
19. Degott C, Zafrani ES, Callard P, Balkau B, Poupon RE, Poupon R. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 1999;29:1007–1012. doi: 10.1002/hep.510290444.
20. Quarneti C, Muratori P, Lalanne C, Fabbri A, Menichella R, Granito A, et al. Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. Liver Int 2014. doi: 10.1111/liv.12560.
21. Lindor KD, Jorgensen RA, Therneau TM, Malinchoc M, Dickson ER. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997;72:1137–1140. doi: 10.4065/72.12.1137.
22. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884–890. doi: 10.1016/S0016-5085(97)70183-5.
23. Poropat G, Giljaca V, Stimac D, Gluud C. Bile acids for liver-transplanted patients. Cochrane Database Syst Rev 2010;(17):CD005442. doi: 10.1002/14651858.CD005442.
24. Angulo P, Dickson ER, Therneau TM, Jorgensen RA, Smith C, DeSotel CK, et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999;30:830–835. doi: 10.1016/S0168-8278(99)80136-6.
25. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006;130:715–720. doi: 10.1053/j.gastro.2005. 12.029.
26. Corpechot C, Abenavoli L, Rabahi N, Chretien Y, Andreani T, Johanet C, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008;48:871–877. doi: 10.1002/hep.22428.
27. Corpechot C, Chazouillres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011;55:1361–1367. doi: 10.1016/j.jhep.2011.02.031.
28. Kumagi T, Guindi M, Fischer SE, Arenovich T, Abdalian R, Coltescu C, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010;105: 2186–2194.
29. Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009;136:1281–1287. doi: 10.1053/j.gastro.2009. 01.003.
30. Momah N, Silveira MG, Jorgensen R, Sinakos E, Lindor KD. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. Liver Int 2012;32:790–795. doi: 10.1111/j.1478-3231.2011.02678.x.
31. Shi TY, Zhang LN, Chen H, Wang L, Shen M, Zhang X, et al. Risk factors for hepatic decompensation in patients with primary biliary cirrhosis. World J Gastroenterol 2013;19:1111–1118.
32. Poupon RE, Bonnand AM, Chretien Y, Poupon R. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology 1999;29:1668–1671. doi: 10.1002/hep.510290603.
33. Floreani A, Caroli D, Variola A, Rizzotto ER, Antoniazzi S, Chiaramonte M, et al. A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre. Liver Int 2011;31:361–368. doi: 10.1111/j.1478-3231.2010.02366.x.
34. ter Borg PC, Schalm SW, Hansen BE, van Buuren HR, Dutch PBC Study Group. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006;101:2044–2050.
35. Lee YM, Kaplan MM. The natural history of PBC: has it changed? Semin Liver Dis 2005;25:321–326. doi: 10.1055/s-2005-916323.
36. Bonnand AM, Heathcote EJ, Lindor KD, Poupon RE. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology 1999;29:39–43. doi: 10.1002/hep.510290140.
37. Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007;5:1313–1315. doi: 10.1016/j.cgh.2007.07.015.
38. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660–678. doi: 10.1002/hep.23294.
39. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995;332: 924–933. doi: 10.1056/NEJM199504063321406.
40. Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003;125: 1364–1369. doi: 10.1016/j.gastro.2003.07.011.
41. Cassinotti A, Birindelli S, Clerici M, Trabattoni D, Lazzaroni M, Ardizzone S, et al. HLA and autoimmune digestive disease: a clinically oriented review for gastroenterologists. Am J Gastroenterol 2009;104:195–217.
42. Folseraas T, Liaskou E, Anderson CA, Karlsen TH. Genetics in PSC: what do the ‘‘risk genes’’ teach us? Clin Rev Allergy Immunol 2014. doi: 10.1038/ajg.2008.10.
43. Chapman RW, Varghese Z, Gaul R, Patel G, Kokinon N, Sherlock S. Association of primary sclerosing cholangitis with HLA-B8. Gut 1983;24: 38–41. doi: 10.1136/gut.24.1.38.
44. Wiencke K, Karlsen TH, Boberg KM, Thorsby E, Schrumpf E, Lie BA, et al. Primary sclerosing cholangitis is associated with extended HLA-DR3 and HLA-DR6 haplotypes. Tissue Antigens 2007;69:161–169. doi: 10.1111/j.1399-0039.2006.00738.x.
45. Mehal WZ, Lo Y-D, Wordsworth BP, Neuberger JM, Hubscher SC, Fleming KA, et al. HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 1994;106:160–167.
46. Prochazka EJ, Terasaki PI, Park MS, Goldstein LI, Busuttil RW. Association of primary sclerosing cholangitis with HLA-DRw52a. N Engl J Med 1990;322: 1842–1844. doi: 10.1056/NEJM199006283222603.
47. Spurkland A, Saarinen S, Boberg KM, Mitchell S, Broome U, Caballeria L, et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 1999;53:459–469. doi: 10.1034/j.1399-0039.1999.530502.x.
48. van Milligen de Wit AW, van Deventer SJ, Tytgat GN. Immunogenetic aspects of primary sclerosing cholangitis: implications for therapeutic strategies. Am J Gastroenterol 1995;90:893–900.
49. Saarinen S, Olerup O, Broomé U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol 2000;95:3195–3199.
50. Loftus EV Jr, Sandborn WJ, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, et al. Primary sclerosing cholangitis is associated with nonsmok-ing: a case-control study. Gastroenterology 1996;110:1496–1502. doi: 10.1053/gast.1996.v110.pm8613055.
51. Mitchell SA, Thyssen M, Orchard TR, Jewell DP, Fleming KA, Chapman RW. Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study. Gut 2002;51:567–573. doi: 10.1136/gut.51.4.567.
52. Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. The Lancet 2013;382:1587–1599. doi: 10.1016/S0140-6736(13)60096-3.
53. Andersen IM, Tengesdal G, Lie BA, Boberg KM, Karlsen TH, Hov JR. Effects of coffee consumption, smoking, and hormones on risk for primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2014;12:1019–1028. doi: 10.1016/j.cgh.2013.09.024.
54. Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998;42:788–791. doi: 10.1136/gut.42.6.788.
55. Terjung B, Worman HJ. Anti-neutrophil antibodies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001;15:629–642. doi: 10.1053/bega.2001.0209.
56. Schulte-Pelkum J, Radice A, Norman GL, Lomicronpez Hoyos M, Lakos G, Buchner C, et al. Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies. J Immunol Res 2014;2014:185416. doi: 10.1155/2014/185416.
57. Plevy S. Do serological markers and cytokines determine the indetermi-nate? J Clin Gastroenterol 2004;38:S51–6. doi: 10.1097/01.mcg. 0000124026.92823.fc.
58. Oudkerk Pool M, Ellerbroek PM, Ridwan BU, Goldschmeding R, von Blomberg BM, Pena AS, et al. Serum antineutrophil cytoplasmic auto-antibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment. Gut 1993;34:46–50. doi: 10.1136/gut.34.1.46.
59. Bansi DS, Fleming KA, Chapman RW. Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass. Gut 1996;38:384–389. doi: 10.1136/gut.38.3.384.
60. Ellerbroek PM, Oudkerk Pool M, Ridwan BU, Dolman KM, von Blomberg BM, von dem Borne AE, et al. Neutrophil cytoplasmic antibodies (p-ANCA) in ulcerative colitis. J Clin Pathol 1994;47:257–262. doi: 10.1136/jcp.47.3.257.
61. Hov JR, Boberg KM, Karlsen TH. Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol 2008;14:3781–3791. doi: 10.3748/wjg.14.3781.
62. Bodenheimer JC Jr, LaRusso NF, Thayer WR Jr, Charland C, Staples PJ, Ludwig J. Elevated circulating immune complexes in primary sclerosing cholangitis. Hepatology 1983;3:150–154. doi: 10.1002/hep.1840030203.
63. Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol 2008;14:331–337.
64. Bergquist A, Lindberg G, Saarinen S, Broomé U. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol 2005;42:252–256. doi: 10.1016/j.jhep.2004.10.011.
65. Bergquist A, Montgomery SM, Bahmanyar S, Olsson R, Danielsson Å, Lindgren S, et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008;6:939–943. doi: 10.1016/j.cgh.2008.03.016.
66. Seibold F, Slametschka D, Gregor M, Weber P. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1994;107:532–536.
67. Loftus EV Jr, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005;54:91– 96. doi: 10.1136/gut.2004.046615.
68. Yimam KK, Bowlus CL. Diagnosis and classification of primary sclerosing cholangitis. Autoimmun Rev 2014;13:445–450. doi: 10.1016/j.autrev.2014.01.040.
69. Broomé U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis 2006;26:31–41. doi: 10.1055/s-2006-933561.
70. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001;96:1116–1122. doi: 10.1111/j.1572-0241.
71. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009;50: 158–164. doi: 10.1016/j.jhep.2008.08.013.
72. Lundqvist K, Broomé U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 1997;40:451–456. doi: 10.1007/BF02258391.
73. Verdonk RC, Dijkstra G, Haagsma EB, Shostrom VK, Van den Berg AP, Kleibeuker JH, et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant 2006;6: 1422–1429. doi: 10.1111/j.1600-6143.2006.01333.x.
74. Sinakos E, Samuel S, Enders F, Loftus EV Jr, Sandborn WJ, Lindor KD. Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship. Inflamm Bowel Dis 2013;19:1004–1009. doi: 10.1097/MIB.0b013e3182802893.
75. Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013;145:521–536. doi: 10.1053/j.gastro.2013.06.052.
76. Bangarulingam SY, Gossard AA, Petersen BT, Ott BJ, Lindor KD. Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am J Gastroenterol 2009;104:855–860. doi: 10.1038/ajg.2008.161.
77. Abdalian R, Heathcote EJ. Sclerosing cholangitis: a focus on secondary causes. Hepatology 2006;44:1063–1074. doi: 10.1002/hep.21405.
78. Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 2002;35:1494– 1500. doi: 10.1053/jhep.2002.33202.
79. Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013;58:2045–2055. doi: 10.1002/hep.26565.
80. Broomé U, Glaumann H, Lindstom E, Loof L, Almer S, Prytz H, et al. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol 2002;36:586–589. doi: 10.1016/S0168-8278(02)00036-3.
81. Floreani A, Rizzotto ER, Ferrara F, Carderi I, Caroli D, Blasone L, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005;100:1516–1522. doi: 10.1111/j.1572-0241.2005.41841.x.
82. Boberg KM, Fausa O, Haaland T, Holter E, Mellbye OJ, Spurkland A, et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996;23:1369–1376. doi: 10.1002/hep.510230612.
83. Trivedi PJ, Chapman RW. PSC, AIH and overlap syndrome in inflammatory bowel disease. Clinics and Research in Hepatology and Gastroenterology 2012;36:420–436. doi: 10.1016/j.clinre.2011.10.007.
84. Ota M, Katsuyama Y, Hamano H, Umemura T, Kimura A, Yoshizawa K, et al. Two critical genes (HLA-DRB1 and ABCF1) in the HLA region are associated with the susceptibility to autoimmune pancreatitis. Immunogenetics 2007; 59:45–52. doi: 10.1007/s00251-006-0178-2.
85. Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008;134:706–715. doi: 10.1053/j.gastro. 2007.12.009.
86. Porayko MK, Wiesner RH, LaRusso NF, Ludwig J, MacCarty RL, Steiner BL, et al. Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology 1990;98:1594–1602.
87. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, Rajaram R, Rauws EA, Mulder CJ, et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 2002;51: 562–566. doi: 10.1136/gut.51.4.562.
88. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006; 12:1813–1824. doi: 10.1002/lt.20910.
89. Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T, et al. Clinically recurrent primary sclerosing cholangitis following liver transplan-tation: a time course. Liver Transpl 2008;14:181–185. doi: 10.1002/lt.21313.
90. Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther 2011;34:901–910. doi: 10.1111/j.1365-2036.2011.04822.x.
91. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808–814. doi: 10.1002/hep.23082.
92. Lee YM, Kaplan MM, Vakil N, Arlow FL, Carey WD, Cheney CP, et al. Management of primary sclerosing cholangitis. Am J Gastroenterol 2002; 97:528–534.
93. Boberg KM, Egeland T, Schrumpf E. Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand J Gastroenterol 2003;38:991–995.
94. Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, et al. Primary biliary cirrhosis: report of a focus study group. Hepatology 2004; 40:1013–1020. doi: 10.1002/hep.1840400434.
95. Talwalkar JA, Souto E, Jorgensen RA, Lindor KD. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2003;1:297–302. doi: 10.1016/S1542-3565(03)00134-4.
96. ter Borg PC, van Os E, van den Broek WW, Hansen BE, van Buuren HR. Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]. BMC Gastroenterol 2004;4:13. doi: 10.1186/1471-230X-4-13.
97. Talwalkar JA, Donlinger JJ, Gossard AA, Keach JC, Jorgensen RA, Petz JC, et al. Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. Dig Dis Sci 2006;51:1985–1991. doi: 10.1007/s10620-006-9397-5.
98. Theal JJ, Toosi MN, Girlan L, Heslegrave RJ, Huet PM, Burak KW, et al. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. Hepatology 2005;41:1305–1312. doi: 10.1002/hep.20698.
99. Prince MI, Mitchison HC, Ashley D, Burke DA, Edwards N, Bramble MG, et al. Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, crossover trial. Aliment Pharmacol Ther 2003;17:137–143. doi: 10.1046/j.1365-2036.2003.01398.x.
100. Jones DE, Newton JL. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther 2007;25:471–476. doi: 10.1111/j.1365-2036.2006.03223.x.
101. Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol 2001;96:2199–2205. doi: 10.1111/j.1572-0241.2001.03956.x.
102. Bolier R, Oude Elferink RP, Beuers U. Advances in pathogenesis and treatment of pruritus. Clin Liver Dis 2013;17:319–329. doi: 10.1016/j.cld.2012.11.006.
103. Jones EA, Bergasa NV. The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology 1990;11:884–887. doi: 10.1002/hep.1840110526.
104. Beuers U, Kremer AE, Bolier R, Elferink RP. Pruritus in cholestasis: facts and fiction. Hepatology 2014;60:399–407. doi: 10.1002/hep.26909.
105. Kremer AE, van Dijk R, Leckie P, Schaap FG, Kuiper EM, Mettang T, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology 2012;56: 1391–1400. doi: 10.1002/hep.25748.
106. Younossi ZM, Kiwi ML, Boparai N, Price LL, Guyatt G. Cholestatic liver diseases and health-related quality of life. Am J Gastroenterol 2000;95: 497–502.
107. Kaplan MM, Elta GH, Furie B, Sadowski JA, Russell RM. Fat-soluble vitamin nutriture in primary biliary cirrhosis. Gastroenterology 1988;95:787–792.
108. Jorgensen RA, Lindor KD, Sartin JS, LaRusso NF, Wiesner RH. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol 1995;20:215–219. doi: 10.1097/00004836-199504000-00011.
109. Phillips JR, Angulo P, Petterson T, Lindor KD. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001;96:2745– 2750. doi: 10.1111/j.1572-0241.2001.04134.x.
110. Kowdley KV. Lipids and lipid-activated vitamins in chronic cholestatic diseases. Clin Liver Dis 1998;2:373–89,x. doi: 10.1016/S1089-3261(05)70013-1.
111. Guichelaar MM, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl 2006;12:1390–1402. doi: 10.1002/lt.20874.
112. Leslie WD, Morin SN. Osteoporosis epidemiology 2013: implications for diagnosis, risk assessment, and treatment. Curr Opin Rheumatol 2014;26: 440–446. doi: 10.1097/BOR.0000000000000064.
113. Ruiz-Gaspa S, Martinez-Ferrer A, Guanabens N, Dubreuil M, Peris P, Enjuanes A, et al. Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases. Hepatology 2011;54:2104–2113. doi: 10.1002/hep.24605.
114. Le Gars L. Bone involvement in patients with chronic cholestasis. Joint Bone Spine 2002;69:373–378. doi: 10.1016/S1297-319X(02)00413-X.
115. Leslie WD, Bernstein CN, Leboff MS, American Gastroenterological Association Clinical Practice Commitee. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003;125:941–966. doi: 10.1016/S0016-5085(03)01062-X.
116. Angulo P, Grandison GA, Fong DG, Keach JC, Lindor KD, Bjornsson E, et al. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 2011;140:180–188. doi: 10.1053/j.gastro.2010.10.014.
117. Millonig G, Graziadei IW, Eichler D, Pfeiffer KP, Finkenstedt G, Muehllechner P, et al. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl 2005;11:960–966. doi: 10.1002/lt.20466.
118. Masaki K, Shiomi S, Kuroki T, Tanaka T, Monna T, Ochi H. Longitudinal changes of bone mineral content with age in patients with cirrhosis of the liver. J Gastroenterol 1998;33:236–240. doi: 10.1007/s005350050076.
119. Iwamoto J, Takada T, Sato Y. Vitamin K nutritional status and under-carboxylated osteocalcin in postmenopausal osteoporotic women treated with bisphosphonates. Asia Pac J Clin Nutr 2014;23:256–262. doi: 10.6133/apjcn.2014.23.2.15.
120. Ruiz-Gaspa S, Guanabens N, Enjuanes A, Peris P, Martinez-Ferrer A, de Osaba MJ, et al. Lithocholic acid downregulates vitamin D effects in human osteoblasts. Eur J Clin Invest 2010;40:25–34. doi: 10.1111/j.1365-2362.2009.02230.x.
121. Dubreuil M, Ruiz-Gaspa S, Guanabens N, Peris P, Alvarez L, Monegal A, et al. Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells. Liver Int 2013;33:1029–1038. doi: 10.1111/liv.12153.
122. Komatsuda A, Wakui H, Ohtani H, Masai R, Okuyama S, Nimura T, et al. Tubulointerstitial nephritis and renal tubular acidosis of different types are rare but important complications of primary biliary cirrhosis. Nephrol Dial Transplant 2010;25:3575–3579. doi: 10.1093/ndt/gfq232.
123. Lino M, Binaut R, Noel LH, Patey N, Rustin P, Daniel L, et al. Tubulointerstitial nephritis and Fanconi syndrome in primary biliary cirrhosis. Am J Kidney Dis 2005;46:e41–e46. doi: 10.1053/j.ajkd.2005.05.021.
124. Pares A, Rimola A, Bruguera M, Mas E, Rodes J. Renal tubular acidosis in primary biliary cirrhosis. Gastroenterology 1981;80:681–686.
125. Sun L, Guo W, Yin C, Zhang S, Qu G, Hou Y, et al. Hepcidin deficiency undermines bone load-bearing capacity through inducing iron overload. Gene 2014;543:161–165. doi: 10.1016/j.gene.2014.02.023.
126. Haider A, Meergans U, Traish A, Saad F, Doros G, Lips P, et al. Progressive improvement of T-scores in men with osteoporosis and subnormal serum testosterone levels upon treatment with testosterone over six years. Int J Endocrinol 2014;2014:496948. doi: 10.1155/2014/496948.
127. Zheng J, Mao X, Ling J, He Q, Quan J. Low serum levels of zinc, copper, and iron as risk factors for osteoporosis: a meta-analysis. Biol Trace Elem Res 2014;160:15–23. doi: 10.1007/s12011-014-0031-7.
128. Ardawi MS, Akhbar DH, Alshaikh A, Ahmed MM, Qari MH, Rouzi AA, et al. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone 2013;56:355–362. doi: 10.1016/j.bone.2013.06.029.
129. Guanabens N, Pares A, Ros I, Caballeria L, Pons F, Vidal S, et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 2005;42:573–577. doi: 10.1016/j.jhep.2004.11.035.
130. Guanabens N, Cerda D, Monegal A, Pons F, Caballeria L, Peris P, et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology 2010;138:2348–2356. doi: 10.1053/j.gastro.2010.02.016.
131. Mounach A, Ouzzif Z, Wariaghli G, Achemlal L, Benbaghdadi I, Aouragh A, et al. Primary biliary cirrhosis and osteoporosis: a case-control study. J Bone Miner Metab 2008;26:379–384. doi: 10.1007/s00774-007-0833-1.
132. Solaymani-Dodaran M, Card TR, Aithal GP, West J. Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. Gastroenterology 2006;131:1752–1757. doi: 10.1053/j.gastro.2006.09.012.
133. Menon KV, Angulo P, Weston S, Dickson ER, Lindor KD. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001;35:316–323. doi: 10.1016/S0168-8278(01)00144-1.
134. Benetti A, Crosignani A, Varenna M, Giussani CS, Allocca M, Zuin M, et al. Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: a controlled longitudinal study. J Clin Gastroenterol 2008;42:306–311. doi: 10.1097/01.mcg.0000248017.31386.39.
135. Rudic JS, Giljaca V, Krstic MN, Bjelakovic G, Gluud C. Bisphosphonates for osteoporosis in primary biliary cirrhosis. Cochrane Database Syst Rev 2011;(12):CD009144. doi:CD009144.
136. Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995;10: 250–256. doi: 10.1002/jbmr.5650100211.
137. Eastell R, Dickson ER, Hodgson SF, Wiesner RH, Porayko MK, Wahner HW, et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991;14:296–300. doi: 10.1002/hep.1840140215.
138. Hodgson SF, Dickson ER, Eastell R, Eriksen EF, Bryant SC, Riggs BL. Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis. Bone 1993;14:819–827. doi: 10.1016/8756-3282(93)90310-7.
139. Anonymous Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;843:1–129.
140. Angulo P, Therneau TM, Jorgensen A, DeSotel CK, Egan KS, Dickson ER, et al. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol 1998;29: 729–735. doi: 10.1016/S0168-8278(98)80253-5.
141. Lindor KD, Janes CH, Crippin JS, Jorgensen RA, Dickson ER. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? Hepatology 1995 21:389–392.
142. Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, et al. Zoledronic acid prevents bone loss after liver transplantation: a rando-mized, double-blind, placebo-controlled trial. Ann Intern Med 2006;144: 239–248. doi: 10.7326/0003-4819-144-4-200602210-00005.
143. Hay JE, Malinchoc M, Dickson ER. A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 2001;34:292–298. doi: 10.1016/S0168-8278(00)00093-3.
144. Floreani A, Zappala F, Fries W, Naccarato R, Plebani M, D’Angelo A, et al. A3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. J Clin Gastroenterol 1997;24:239–244. doi: 10.1097/00004836-199706000-00012.
145. Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005;42:762–771. doi: 10.1002/hep.20866.
146. Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Hormone replacement for osteoporosis in women with primary biliary cirrhosis. Cochrane Database Syst Rev 2011;(12):CD009146. doi: 10.1002/14651858.CD009146.pub2.
147. Menon KV, Angulo P, Boe GM, Lindor KD. Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis. Am J Gastroenterol 2003;98:889–892. doi: 10.1111/j.1572-0241.2003.07341.x.
148. Olsson R, Mattsson LA, Obrant K, Mellstrom D. Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis. Liver 1999; 19:188–192. doi: 10.1111/j.1478-3231.1999.tb00034.x.
149. Crippin JS, Jorgensen RA, Dickson ER, Lindor KD. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 1994;89:47–50.
150. Boone RH, Cheung AM, Girlan LM, Heathcote EJ. Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. Dig Dis Sci 2006;51:1103–1112. doi: 10.1007/s10620-006-8015-x.
151. Van Erpecum KJ, Van Berge Henegouwen GP, Verschoor L, Stoelwinder B, Willekens FL. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women. Gastroenterology 1991;100:482– 488.
152. Ko DT, Wijeysundera HC, Udell JA, Vaccarino V, Austin PC, Guo H, et al. Traditional cardiovascular risk factors and the presence of obstructive coronary artery disease in men and women. Can J Cardiol 2014;30:820– 826. doi: 10.1016/j.cjca.2014.04.032.
153. Jahn CE, Schaefer EJ, Taam LA, Hoofnagle JH, Lindgren FT, Albers JJ, et al. Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 1985;89:1266–1278.
154. Longo M, Crosignani A, Battezzati PM, Squarcia Giussani C, Invernizzi P, Zuin M, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 2002;51:265–269. doi: 10.1136/gut.51.2.265.
155. Cash WJ, O’Neill S, O’Donnell ME, McCance DR, Young IS, McEneny J, et al. Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver Int 2013;33:1166–1174. doi: 10.1111/liv.12191.
156. Miller JP. Dyslipoproteinaemia of liver disease. Baillieres Clin Endocrinol Metab 1990;4:807–832. doi: 10.1016/S0950-351X(05)80080-1.
157. Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipide-mia, and atherosclerotic risk: a systematic review. Atherosclerosis 2007; 194:293–299. doi: 10.1016/j.atherosclerosis.2006.11.036.
158. Walli A K, Seidel D. Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-hydroxy-3-methylglutaryl coenzyme A reductase and chylomicron remnant removal in human fibroblasts, lymphocytes, and in the rat. J Clin Invest 1984;74: 867–879. doi: 10.1172/JCI111504.
159. Chang PY, Lu SC, Su TC, Chou SF, Huang WH, Morrisett JD, et al. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res 2004;45:2116–2122. doi: 10.1194/jlr.M400229-JLR200.
160. Edwards CM, Otal MP, Stacpoole PW. Lipoprotein-X fails to inhibit hydro-xymethylglutaryl coenzyme A reductase in HepG2 cells. Metabolism: Clinical and Experimental 1993;42:807–813. doi: 10.1016/0026-0495(93)90051-O.
161. Crippin JS, Lindor KD, Jorgensen R, Kottke BA, Harrison JM, Murtaugh PA, et al. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? Hepatology 1992;15:858–862. doi: 10.1002/hep.1840150518.
162. Van Dam GM, Gips CH. Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures. Scand J Gastroenterol 1997;32:77–83.
163. Sinakos E, Abbas G, Jorgensen RA, Lindor KD. Serum lipids in primary sclerosing cholangitis. Dig Liver Dis 2012;44:44–48. doi: 10.1016/j.dld.2011.07.020.
164. Ludvigsson JF, Bergquist A, Montgomery SM, Bahmanyar S. Risk of diabetes and cardiovascular disease in patients with primary sclerosing cholangitis. J Hepatol 2014;60:802–808. doi: 10.1016/j.jhep.2013.11.017.
165. Ahrens EH Jr, Kunkel HG. The relationship between serum lipids and skin xanthomata in 18 patients with primary biliary cirrhosis. J Clin Invest 1949; 28:1565–1574. doi: 10.1172/JCI102222.
166. Ambinder EP, Cohen LB, Wolke AM, Field SP, Adelsberg B, Schaffner F, et al. The clinical effectiveness and safety of chronic plasmapheresis in patients with primary biliary cirrhosis. J Clin Apheresis 1985;2:219–223. doi: 10.1002/jca.2920020303.
167. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889–2934. doi: 10.1016/j.jacc.2013.11.002.
168. Pencina MJ, Navar-Boggan AM, D’Agostino RB Sr, Williams K, Neely B, Sniderman AD, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med 2014;370:1422–1431. doi: 10.1056/NEJMoa1315665.
169. Kurihara T, Akimoto M, Abe K, Ishiguro H, Niimi A, Maeda A, et al. Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia. Clin Ther 1993;15:890–898.
170. Ritzel U, Leonhardt U, Näther M, Schäfer G, Armstrong VW, Ramadori G. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol 2002; 36:454–458. doi: 10.1016/S0168-8278(02)00006-5.
171. Del Puppo M, Galli Kienle M, Crosignani A, Petroni ML, Amati B, Zuin M, et al. Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration. J Lipid Res 2001;42:437–441.
172. Balan V, Dickson ER, Jorgensen RA, Lindor KD. Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis. Mayo Clin Proc 1994;69:923–929. doi: 10.1016/S0025-6196(12)61815-1.
173. Gandelman G, Aronow WS, Weiss MB. Resolving hyperlipidemia after liver transplantation in a patient with primary sclerosing cholangitis. Am J Ther 2006;13:171–174.
174. Hay JE. Liver disease in pregnancy. Hepatology 2008;47:1067–1076. doi: 10.1002/hep.22130.
175. Lata I. Hepatobiliary diseases during pregnancy and their management: an update. Int J Crit Illn Inj Sci 2013;3:175–182. doi: 10.4103/2229-5151.119196.
176. Than NN, Neuberger J. Liver abnormalities in pregnancy. Best Pract Res Clin Gastroenterol 2013;27:565–575. doi: 10.1016/j.bpg.2013.06.015.
177. Everson GT. Liver problems in pregnancy: distinguishing normal from abnormal hepatic changes. Medscape Womens Health 1998;3:3.
178. Trivedi P J, Kumagi T, Al-Harthy N, Coltescu C, Ward S, Cheung A, et al. Good maternal and fetal outcomes for pregnant women with primary biliary cirrhosis. Clinical Gastroenterology and Hepatology 2014;12:1179– 1185.e1. doi: 10.1016/j.cgh.2013.11.030.
179. Efe C, Kahramanoglu-Aksoy E, Yilmaz B, Ozseker B, Takci S, Roach EC, et al. Pregnancy in women with primary biliary cirrhosis. Autoimmun Rev 2014;13:931–935. doi: 10.1016/j.autrev.2014.05.008.
180. Floreani A, Infantolino C, Franceschet I, Tene IM, Cazzagon N, Buja A, et al. Pregnancy and primary biliary cirrhosis: a case-control study. Clin Rev Allergy Immunol 2014.
181. Cresswell JA, Ronsmans C, Calvert C, Filippi V. Prevalence of placenta praevia by world region: a systematic review and meta-analysis. Trop Med Int Health 2013;18:712–724. doi: 10.1111/tmi.12100.
182. Janczewska I, Olsson R, Hultcrantz R, Broome U. Pregnancy in patients with primary sclerosing cholangitis. Liver 1996;16:326–330. doi: 10.1111/j.1600-0676.1996.tb00754.x.
183. Wellge BE, Sterneck M, Teufel A, Rust C, Franke A, Schreiber S, et al. Pregnancy in primary sclerosing cholangitis. Gut 2011; 60:1117–1121. doi: 10.1136/gut.2010.228924.
184. Ludvigsson JF, Bergquist A, Ajne G, Kane S, Ekbom A, Stephansson O. A population-based cohort study of pregnancy outcomes among women with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2014;12:95– 100. doi: 10.1016/j.cgh.2013.07.011.
185. Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatology 2004;40:467–474. doi: 10.1002/hep.20336.
186. Brites D, Rodrigues CM. Elevated levels of bile acids in colostrum of patients with cholestasis of pregnancy are decreased following ursodeoxycholic acid ther-apy. J Hepatol 1998;29:743–751. doi: 10.1016/S0168-8278(98)80255-9.
187. Meng LJ, Reyes H, Axelson M, Palma J, Hernandez I, Ribalta J, et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology 1997;26:1573–1579. doi: 10.1002/hep.510260627.
188. Poupon R, Chretien Y, Chazouilleres O, Poupon RE. Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis. J Hepatol 2005; 42:418–419. doi: 10.1016/j.jhep.2004.08.029.
189. Boregowda G, Shehata HA. Gastrointestinal and liver disease in pregnancy. Best Pract Res Clin Obstet Gynaecol 2013;27:835–853. doi: 10.1016/j.bpobgyn.2013.07.006.
190. Gurung V, Middleton P, Milan SJ, Hague W, Thornton JG. Interventions for treating cholestasis in pregnancy. Cochrane Database Syst Rev 2013;6: CD000493. doi: 10.1002/14651858.CD000493.pub2.
191. Lucey MR, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013;19:3–26. doi: 10.1002/lt.23566.
192. Fevery J, Henckaerts L, Van Oirbeek R, Vermeire S, Rutgeerts P, Nevens F, et al. Malignancies and mortality in 200 patients with primary sclerosing cholangitis: a long-term single-centre study. Liver Int 2012;32:214–222. doi: 10.1111/j.1478-3231.2011.02575.x.
193. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53: 1020–1022. doi: 10.1002/hep.24199.
194. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W, Practice Guidelines Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46:922– 938. doi: 10.1002/hep.21907.
195. The Johns Hopkins School of Medicine Department of Gynecology. The Johns Hopkins Manual of Gynecology and Obstetrics: Lippincott Williams & Wilkins.
196. Ambros-Rudolph CM, Mullegger RR, Vaughan-Jones SA, Kerl H, Black MM. The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients. J Am Acad Dermatol 2006;54:395–404. doi: 10.1016/j.jaad.2005.12.012.
197. Vaughan Jones SA, Hern S, Nelson-Piercy C, Seed PT, Black MM. A prospective study of 200 women with dermatoses of pregnancy correlating clinical findings with hormonal and immunopathological profiles. Br J Dermatol 1999;141:71–81. doi: 10.1046/j.1365-2133.1999.0 2923.x.